



OFFICE of the DEPUTY PRIME MINISTER  
MINISTRY for HEALTH  
15, PALAZZO CASTELLANIA, MERCHANTS STREET, VALLETTA, MALTA

**DH Circular 7/2021**  
DH 1503/2015

4<sup>th</sup> February 2021

**Attention All:** Consultants  
Medical Officers  
Pharmacists  
Pharmacy Technicians  
Nurses

**Re: New Indication for Everolimus 5mg and 10mg Tablets**

As part of Government's initiative to continue increasing the access to medicines, it is being brought to your attention that a new indication was added to Everolimus 5mg and 10mg tablets.

Everolimus 5mg and 10mg tablets can now be prescribed for neuroendocrine tumours by Consultant Oncologists as per updated protocol 302 attached (Annex 1).

For your attention please.

Dr. Denis Vella Baldacchino  
Chief Medical Officer

## **Everolimus 5mg and 10mg Tablets**

### **Part A**

**Prescriber Criteria:** Consultant Oncologist

**Out-patient and In-patient use:**

1. Malignant Diseases

- ***Breast Cancer***

To be used for the treatment of hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.

- ***Neuroendocrine Tumours***

To be used for the treatment of neuroendocrine tumours.

**Duration of approval:**

1 year

### **Part B**

**Prescriber Criteria:** Consultant Oncologist

**Out-patient and in-patient use:**

1. Malignant Diseases

For patients with advanced/metastatic renal cell carcinoma whose disease has progressed on or after treatment with VEGF-targeted therapy.

**Duration of approval:**

6 months